Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Yamato-shi, Kanagawa, Japan Clinical Trials

A listing of Yamato-shi, Kanagawa, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Part 1 of this trial will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and the safety profile of tisotumab vedotin in subjects with solid malignancies. Part 2 of this trial will enroll subjects with cervical cancer to provide further data on the safety, tolerability, ...

Phase

3.96 miles

Learn More »

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

The primary objectives are to determine the safety and efficacy of oral larotrectinib in pediatric patients with advanced solid or primary central nervous system (CNS) tumors. The secondary objectives comprise e.g. the determination of the pharmacokinetic properties, the maximum tolerated dose/ recommended dose and the tumor-type specific efficacy of larotrectinib. ...

Phase

8.2 miles

Learn More »

A Study of Brentuximab Vedotin + Adriamycin Vinblastine and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with ...

Phase

9.27 miles

Learn More »

The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part

Phase

9.75 miles

Learn More »

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell lymphoma (MCL), and the safety and tolerability will be investigated in patients with recurrent/refractory diffuse large B-cell lymphoma (DLBCL).

Phase

9.96 miles

Learn More »